After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
Amid growing demand for such treatments, significant advancements in drug development are increasingly focused on long-term sustainability and safety to meet the needs of individuals struggling with weight maintenance. Eli Lilly and Co (NYSE: LLY ) on Thursday shared topline results from the ATTAIN-MAINTAIN Phase 3 trial of orforglipron. The Phase 3 study evaluated orforglipron for weight maintenance over 52 weeks after initial treatment for 72 weeks with the highest tolerated doses of Novo Nordisk A/S ‘ (NYSE: NVO Wegovy (semaglutide) or Zepbound (tirzepatide), in participants from SURMOUNT-5 who were offered the opportunity to be re-randomized to receive orforglipron or placebo. Don't Miss: The ‘ChatGPT of Marketing' Just Opened a $0.85/Share Round — 10,000+ Investors Are Already In An EA Co-Founder Shapes This VC Backed Marketplace— Now You Can Invest in Gaming's Next Big Platform At one year, orforglipron met the primary and all key secondary endpoints compared to pla
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Sanford C. Bernstein.MarketBeat
- Morning Update: How to make a giant crossword [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Eli Lilly (LLY) Gains Support From Daiwa and Goldman Sachs in Back-to-Back Calls [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (NYSE:LLY) had its "outperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Market Voices: Lilly's new obesity pill, NYSE owner eyes crypto firm [Seeking Alpha]Seeking Alpha
LLY
Earnings
- 10/30/25 - Beat
LLY
Sec Filings
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- 12/16/25 - Form 4
- LLY's page on the SEC website